Monte Rosa Therapeutics, Inc. (GLUE)
NASDAQ: GLUE · Real-Time Price · USD
17.46
-0.34 (-1.91%)
Mar 9, 2026, 2:01 PM EDT - Market open
Monte Rosa Therapeutics Employees
Monte Rosa Therapeutics had 134 employees as of December 31, 2024. The number of employees increased by 1 or 0.75% compared to the previous year.
Employees
134
Change (1Y)
1
Growth (1Y)
0.75%
Revenue / Employee
$1,234,952
Profits / Employee
$142,490
Market Cap
1.38B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 134 | 1 | 0.75% |
| Dec 31, 2023 | 133 | 10 | 8.13% |
| Dec 31, 2022 | 123 | 30 | 32.26% |
| Dec 31, 2021 | 93 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Ardelyx | 489 |
| Biohaven | 256 |
| Zenas BioPharma | 130 |
| MoonLake Immunotherapeutics | 130 |
| Kodiak Sciences | 123 |
| Olema Pharmaceuticals | 122 |
| Savara | 59 |
| AtaiBeckley | 54 |
GLUE News
- 13 days ago - Monte Rosa Therapeutics Presents Updated Clinical Data from Phase 1/2 Study of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients at ASCO Genitourinary Cancers Symposium (ASCO GU) - GlobeNewsWire
- 14 days ago - Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering - GlobeNewsWire
- 2 months ago - Monte Rosa Therapeutics: Competitive MRT-8102 Results Offer Additional Platform Validation - Seeking Alpha
- 2 months ago - Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 2 months ago - Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating Profound CRP Reductions in Elevated CVD-risk Subjects - GlobeNewsWire
- 2 months ago - Monte Rosa Therapeutics to Present Interim MRT-8102 Phase 1 Study Results - GlobeNewsWire
- 2 months ago - Why Is Monte Rosa Stock Trading Higher Today? - Benzinga